Education
About Us
Working with TipRanks
Follow Us
Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
DRTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.11 - $4.39
Previous CloseN/A
Volume116.73K
Average Volume (3M)55.64K
Market Cap
$281.20M
Enterprise Value$180.76M
Total Cash (Recent Filing)$51.64M
Total Debt (Recent Filing)$12.29M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 25, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding84,699,720
10 Day Avg. Volume61,767
30 Day Avg. Volume55,640
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.64
Forecast
1Y Price Target
$8.50Price Target Upside156.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical ResultsAlpha Tau Medical reported positive interim results for the first eight patients receiving a combination of Alpha DaRT and Keytruda for the treatment of recurrent unresectable or metastatic head and neck squamous cell carcinoma, with a systemic objective response rate of 75%.
Clinical TrialsThe company is slated to start patient enrollment for a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with newly diagnosed pancreatic cancer.
Strategic InvestmentA $36.9M strategic investment from Oramed validates Alpha Tau’s novel technology and its potential in oncology therapeutics.
Bears Say
Financial PerformanceNet loss was $10.1M, or ($0.13) per share, moderately higher than the estimated loss of $9.3M.
Regulatory RisksRisks include failure of Alpha DaRT in clinical trials, failure to secure regulatory approval in the U.S., failure to achieve commercial success, and potential dilution risk.
Alpha Tau Medical Ltd News
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $2.11 and its highest was $4.39 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $281.20M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is Nov 25, 2025 which is in 88 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on Aug 11, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.019.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.11.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 84,699,720 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went down -8.708%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
Alpha Tau Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (156.02% Upside)
$8.50 (156.02% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ―
Last 30 Days ―
Last 30 Days ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.90%
12-Months-Change
Fundamentals
Return on Equity
-43.83%
Trailing 12-Months
Asset Growth
15.52%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$8.50
▲(156.02% Upside)
Technical Analysis
Annexon Biosciences
―
Foghorn Therapeutics
―
Inhibikase Therapeutics
―
Nanobiotix
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
0.04% Mutual Funds
0.61% Other Institutional Investors
99.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---